medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 3

<< Back Next >>

Med Int Mex 2023; 39 (3)

Hyperthyroid hypokalemic periodic paralysis

Torres-Villa JP, Torres-Torres JM, Acosta-Acosta J

Language: Spanish
References: 25
Page: 568-581
PDF size: 229.20 Kb.


ABSTRACT

Background: Prevalence of thyroid diseases has increased over time worldwide, being especially identified in women; however, its complications affect both sexes equally.
Clinical case: A 31-year-old male patient with multiple hospital admissions due to hypokalemic hyperthyroid periodic paralysis. Patient of case reported started with a hydroelectrolytic imbalance attributed to the chronic illnesses that he presented and with later analysis a thyroid condition was identified. Through the analysis of complementary examinations and the identification of the patient’s regular medication, it was concluded that the thyroid disease was the precursor of the constant hydroelectrolyte imbalances.
Conclusions: The personalized and individual analysis of each case is a feasible alternative to diseases that are difficult to diagnose


REFERENCES

  1. Leo S De, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016; 388: 906-18. https://doi.org/10.1016/S0140-6736(16)00278-6.

  2. MSP. Perfil de morbilidad ambulatoria. 2017

  3. Claudio Liberman DG. Prevalencia e incidencia de los principalestrastornos endocrinos y metabólicos prevalenceand incidence of the principal endocrine and metabolicdisorders. Rev Med Clín Las Condes 2013; 24 (5): 735-41.DOI: 10.1016/S0716-8640(13)70217-7.

  4. Olga M, Pereira-Despaigne L. Medicina alternativa. Apiterapiaen pacientes con descompensación moderadadel bocio tóxico difuso. Apitherapy in patients with milddescompensation of the diffuse toxic goiter. Medisan 2011;15 (10): 1499-502.

  5. Maia LA, Scheffel RS, Laurini E, Meyer S, Mazeto GMFS,Amaral De Rincón Y, Pacheco J, Mederico M, Gómez-PérezR, De Trabajo G. Terapéutica en bocio multinodular (Bmn).Rev Venez Endocrinol Metab 2013; 11 (1): 18-25.

  6. Gauna A, Ana Fadel A, Gutiérrez S, Novelli JL, Orlandi AM,Parma R, et al. Tratamiento del hipertiroidismo por Enfermedadde Graves en pacientes adultos no embarazadas.Rev Argent Endocrinol Metab 2013; 50 (2): 107-26.

  7. Patel K, McCoy JV, Davis PM. Recognizing thyrotoxic hypokalemicperiodic paralysis. J Am Acad Phys Assist 2018;31 (1): 31-34. doi:10.1097/01.jaa.0000527697.21783.5a.

  8. Fatourechi V. Hyperthyroidism and thyrotoxicosis.Mayo Clinic 2013; 9-21. http://dx.doi.org/10.1016/j.emc.2013.12.001.

  9. Lee J, Lee DH, Oh TJ, Kim KM. Clinical feasibility of continuouslymonitored data for heart rate, physical activity,and sleeping by wearable activity trackers in patients withthyrotoxicosis: Protocol for a prospective longitudinalobservational study. JMIR Res Protoc 2018; 7 (2): e49. doi:

  10. 10.2196/resprot.8119.10. Carlé A, Andersen SL, Boelaert K, Laurberg P. Subclinicalthyrotoxicosis: Prevalence, causes and choice of therapy.Eur J Endocrinol 2017; 4835 (March): 1-30. doi: 10.1530/EJE-16-0276.

  11. Alfadda AA, Sallam RM, Elawad GE, Aldhukair H, AlyahyaMM. Subacute thyroiditis: Clinical presentation andlong term outcome. Int J Endocrinol 2014; 2014. doi:10.1155/2014/794943.

  12. Rizzo LFL, Mana DL, Bruno OD. Tiroiditis no-autoinmunes.Medicina (Buenos Aires) 2014; 5411: 481-92.

  13. Blanco Sánchez T, Sanz Fernández M, Castro Gómez M,Muñoz Calvo Ríos MT, et al. Tirotoxicosis facticia y trastornode la conducta alimentaria. An Pediatría 2014; 80: 133-4.

  14. Burch HB, Cooper DS, Ross DS, Greenlee MC, Laurberg P,Maia AL, et al. 2016 American Thyroid Association Guidelinesfor Diagnosis and Management of Hyperthyroidismand Other Causes of Thyrotoxicosis. Thyroid 2016; 26 (10).doi: 10.1089/thy.2016.0229.

  15. Macías-Ortega MM. Parálisis periódica hipopotasémicafamiliar, Instituto Hondureño de Seguridad Social, Serviciode Medicina Interna. Universidad Nacional Autónoma deHonduras. Rev Fac Cienc Méd 2019.

  16. León J, Muñoz N, Rivero A. Parálisis periódica hipopotasémicatirotóxica, a propósito de un caso. Medicina Clínica2018. doi:10.1016/j.medcli.2018.07.008.

  17. Urbina-Soto L, Hernández-Martínez P, Ortiz-Flores F, HernándezJL. Thyrotoxic hypokalemic periodic paralysis. QJMInt J Med 2018. doi:10.1093/qjmed/hcy186.

  18. Rasheed E, Seheult J, Gibney J, Boran G. Does thyrotoxic periodicparalysis have a genetic predisposition? A case report.Ann Clin Biochem 2018. doi:10.1177/0004563218785395.

  19. Machuca-Chaparro S, Riva-Zelada A, Dávalos-González K.Parálisis periódica hipopotasémica tirotóxica. A propósitode un caso. Facultad de Medicina Humana de la UniversidadCatólica “Nuestra Señora de la Asunción”, Asunción-Paraguay. CIMEL 2016; 21 (2): 59-61.

  20. Frantchez V, Valiño J, Carracelas A, Dufrechou C. Parálisisperiódica hipopotasémica tirotóxica: Caso clínico [Thyrotoxichypokalemic periodic paralysis: report of one case].Rev Med Chil 2010; 138 (11): 1427‐1430. DOI: 10.1016/j.semerg.2012.08.005.

  21. Pinel-Ríos FJ, García-Martín G, Serrano-Castro V, Romero-Acebal M. A propósito de un caso de parálisis periódicahipopotasémica tirotóxica [A case report of thyrotoxichypokalemic periodic paralysis]. Rev Neurol 2013; 56 (8):441‐ 442.

  22. Santiago-Pérez S, Pérez-Conde MC. Parálisis periódica hipopotasémica:prueba de ejercicio. Rev Neurol 2012; 35 (8):738‐740. DOI: https://doi.org/10.33588/rn.3508.2002074.

  23. Sobarzo P, Vergara V. Parálisis periódica tirotóxica. Reportede un caso. Revista Científica en Ciencias de la Salud2020; 2 (1).

  24. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet 2012; 379:1155-66. doi: 10.1016/S0140-6736(11)60782-4.

  25. Vázquez C, Torres NL, Villena LA, Scapellato JL, NarváezN. Parálisis periódica hipopotasémica tirotóxica (PPHT):una urgencia metabólica. Rev Esp Casos Clin Med Intern(RECCMI) 2017; 2 (3): 131-133.




2020     |     www.medigraphic.com